Just now, for the first time in human history, AI has been used to cure cancer.

Just now, for the first time in human history, cancer has been cured with the assistance of AI!

Tonight, the global medical community has witnessed a history-shaking earthquake that will be recorded in the annals of human progress.

Global mRNA giant Moderna and Merck jointly announced —

Their first-ever personalized mRNA cancer therapy intismeran autogene has achieved historic success in the global Phase III clinical trial targeting high-risk melanoma.

The two key endpoints of "Recurrence-Free Survival" and "Distant Metastasis-Free Survival" have both been fully met!

The moment the news broke, Wall Street instantly erupted in excitement.

Moderna's stock price soared by more than 100% to 170% in a single day, with its market value increasing by hundreds of billions of dollars out of thin air.

Merck's stock price rose in tandem, and the Nasdaq Biotechnology Index even hit a new all-time high!

However, what is even more admirable is the revolutionary significance behind this technology.

This is the world's first exclusive mRNA anti-cancer drug in human history that truly involves deep AI participation in target design and is customized privately based on the gene mutations of cancer cells in the patient's body!

Elon Musk stated bluntly: Artificial RNA essentially turns disease treatment into a software problem.

Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy in the United States, went even further:

This major victory marks that the treatment of solid tumors has officially entered a brand new era of immunotherapy. This is an extremely bright beginning, and the curtain of the new era has been raised!

Remember this day. In 2020, mRNA technology took only 11 months to go from viral sequencing to vaccine approval, helping humanity survive a major pandemic. In 2026, the same platform, empowered by AI, defeated cancer head-on in a Phase III clinical trial for the first time.

The "Black Reaper": The Century-Old Nightmare on Humanity's Anti-Cancer Journey

To understand how great this breakthrough is, we must first see the ferocity of the opponent we are facing.

This clinical trial targets melanoma. Although it accounts for only about 1% of all skin cancers, it is highly malignant and is one of the leading causes of death from skin cancer.

Melanoma is known as one of the "kings of cancers" for extremely cruel reasons.

It often develops from a seemingly insignificant mole lesion; if you are not careful, it will quickly spread through the lymph and blood to core organs such as the lungs, liver, and brain.

Moreover, it has an extremely high recurrence rate. Even if the tumor is surgically removed, the tiny residual cancer cells lurking in the body will make a comeback within 2 to 3 years after surgery.

For many years, the most effective treatment for it is Merck's "king of drugs" — Keytruda (anti-PD-1 antibody).

The principle of Keytruda is to "release the immune brake of the human body" and let T cells attack cancer cells.

But it has a fatal shortcoming: if the patient's own immune system cannot even "recognize" what the lurking cancer cells look like, even if the brake is released, the immune army will just wander aimlessly inside the body.

Postoperative recurrence, distant metastasis, drug resistance... millions of patients still have to suffer from these torments.

And this time, humanity has finally waited for a "searchlight" that can illuminate the camouflage of cancer cells in the dark.

AI Issues an Exclusive "Warrant" to the Immune System

Moderna and Merck have created a real era of "one drug for one person".

The core of this entire treatment process is the AI algorithm.

This subversive, surgical-level precision therapy can identify mutations and find the "fingerprint" of cancer cells.

Doctors remove the patient's tumor tissue, draw a sample of healthy blood, and perform comprehensive high-throughput gene sequencing. By comparing the DNA of healthy cells and cancer cells, the unique gene mutations of the patient's tumor can be identified.

Next, AI takes over and locks in the most lethal "34 targets" from tens of thousands of mutations.

There may be tens of thousands of mutations in each patient's body, but which of these mutations can activate the immune system to the greatest extent?

Relying solely on human scientists to screen them one by one through experiments would take years or even decades, which patients simply cannot afford to wait.

This is when the large AI model comes into play.

Moderna's deeply integrated AI algorithm frantically deduces protein folding, binding force prediction and immune response simulation within a few hours, and finally accurately selects up to 34 "neoantigens" with the most powerful immune killing effect from the massive number of mutations.

Ultra-Fast Customization: One Exclusive mRNA for One Person

Moderna's super automation platform quickly writes and synthesizes a string of mRNA sequences exclusive to the patient based on these 34 exclusive targets selected by AI, and encapsulates them in lipid nanoparticles (LNPs).

When this unique vaccine is injected into the patient's body, it will instruct healthy cells to express these 34 mutant protein fragments that only exist on cancer cells.

This is equivalent to directly handing the "3D high-definition warrant" for the latent cancer cells in the patient's body to the immune T cells!

At this time, by combining the injection of Keytruda to release the immune brake, the fully trained, fully armed T cell army will launch a carpet search in every corner of the whole body, accurately hunt down and completely eliminate any hidden cancer cells that have luckily survived!

It does no harm to innocent normal cells, and only chases and kills cancer cells with specific mutations — this is the precision medicine that humanity has dreamed of for decades!

After administration, the neoantigen sequences encoded by mRNA are translated in vivo and presented to the immune system, which is a key step in generating a specific T cell response against cancer cells. The mRNA sequences are transient and will not integrate into human DNA

Crossing the "Valley of Death": The First mRNA Cancer Therapy to Achieve Victory in Phase III Trials

In the drug R&D industry, there is a universally accepted iron law: "Phase II brings hope, Phase III buries everything."

Countless anti-cancer miracle drugs and cancer vaccines that were once highly expected have finally fallen in large-scale, extremely strict randomized double-blind Phase III clinical trials.

But this time, Moderna and Merck have created a miracle!

This is a large global Phase III clinical trial that enrolled 1,137 patients with stage IIB to IV high-risk melanoma whose lesions have been surgically removed.

The trial adopts the highest standard of randomized, double-blind, placebo-controlled design:

One group received: combined therapy of personalized mRNA vaccine + Keytruda;

The other group received: standard therapy (Keytruda alone) for about one year.

The interim analysis results have completely shocked the clinical medicine community.

First of all, the primary endpoint was a complete victory.

The mRNA vaccine combination group showed a statistically highly significant and clinically meaningful extension in Recurrence-Free Survival (RFS)!

Secondly, all secondary endpoints were fully met: it significantly reduced the risk of tumor distant spread and metastasis to distant parts of the body (such as lungs, brain, liver) (DMFS endpoint achieved)!

In addition, it has excellent safety performance.

The two companies confirmed that no new unexpected safety signals appeared in the combined treatment, the side effects were generally similar to those of ordinary vaccines, and the treatment was well tolerated.

It should be noted that in the previously announced long-term follow-up data of Phase IIb trial, this combined therapy directly reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% in patients over a period of up to 5 years!